List view / Grid view

Celldex Therapeutics

 

Characterising therapeutic antibodies and ADCs using mass spectrometry

24 August 2016 | By

Since the 1970s, the advent of biotechnology has resulted in the development and commercialisation of many therapeutic proteins, including antibodies and antibody fragments, for the treatment of human diseases. Examples include antibody treatments for autoimmune diseases (for example, adalimumab [Humira┬«] for rheumatoid arthritis), cancers (such as trastuzumab [Herceptin┬«] for breast…

Send this to a friend